Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus PENICILLIN G POTASSIUM.
CLOXAPEN vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic